Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (228)	6/14/2002 2:49:44 AM
From: Czechsinthemail	Read Replies (1) \| Respond to of 598

Improvement over dox seems like a reasonable expectation either as improved efficacy or a better side effect profile or hopefully both. Going forward at a higher dosage seems predicated on being able to get more benefit without significant serious side effect. As I recall, they did discuss the shortened dose administration some during the last quarter's conference call. I can't remember the details. What did they have to say about it during the breakout session? As for the combo trial, I assumed it was in place to explore improvement provided by T67+dox over dox alone. They seem to be confident that T67 will do better than dox, though perhaps not so confident that they didn't want a backup. That was my understanding of the Ph II combo. I'm looking forward to their announcement of new IND's. Do you have any more info on PPar-g? I'm also curious if they provided more information about potential partnerships. I believe he said they were hoping to announce 1 or 2 more this year.